Sharon Friedlander

Sharon Friedlander is an accomplished professional in the field of oncology and translational medicine with extensive experience in leading research and development initiatives. Currently serving as the Associate Director and Reverse Translation Development Lead at Takeda Oncology since September 2017, Sharon has also held the position of Associate Director, Translational Medicine Lead for the IO-ODDU division. Prior to Takeda, Sharon worked at Deciphera Pharmaceuticals as Associate Director, Head of Translational Medicine, and at Karyopharm Therapeutics Inc. as Associate Director, Head of Translational Research, and Senior Scientist. Earlier career experience includes a role at Metamark Genetics as Senior Scientist and Corporate-Pharma Partnerships Lead. Sharon's educational background includes a Postdoctoral Fellowship in Integrative Cancer Research from the Massachusetts Institute of Technology and a Ph.D. in Medical Sciences from The Hebrew University Hadassah Medical School, along with a Master's in Microbiology and a Bachelor's in Life Science from The Hebrew University.